The 2014 elections created a lot of excitement among marijuana supporters, as voters in Oregon, Alaska, and the District of Columbia expanded the number of jurisdictions allowing recreational marijuana use.
This has policy makers thinking 2016 could yield a flurry of additional ballot measures that further expand the legal marijuana market. If so, much of the debate would center on the medical benefits of marijuana in key indications such as cancer pain, diabetes, mental health, and epilepsy. As such, investors hoping to benefit from medical marijuana are focusing on drug companies that seek to profit from developing marijuana-derived medicines. The two drugmakers that seem best positioned to capitalize on that opportunity are GW Pharmaceuticals Plc (NASDAQ: GWPH ) and Insys Therapeutics (NASDAQ: INSY ) , so let’s learn more about them.